Fundz

Who to call at Arcus Biosciences, and when

Fundz watches for the moments Arcus Biosciences starts buying, and tells you who to reach.

  • An alert the day Arcus Biosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Arcus Biosciences, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

LaunchArcus Biosciences, Inc. presents promising data for casdatifan, a HIF-2a inhibitor, aimed at treating metastatic kidney cancer.

Feb 15, 2025
HaywardBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Product Description

Arcus Biosciences, Inc. shared new data regarding casdatifan, demonstrating its best-in-class potential for treating metastatic kidney cancer at the 2025 ASCO Genitourinary Cancers Symposium, highlighting its confirmed response rate and tolerability in patients.

Company Information

Company

Arcus Biosciences

Location

Hayward, California, United States

About

Arcus Biosciences, Inc. is a clinical-stage, global biopharmaceutical company, focused on developing differentiated molecules and combination therapies for people with cancer.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Arcus Biosciences ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Arcus Biosciences's next move

Learn about Strategic plan

Product Launch Insights

What this usually means
Market expansion signals
New product launches often coincide with market expansion initiatives

Arcus Biosciences shipped something new. Fundz reads product launches, trademark filings and hiring together.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.